An observational study in Liver Cirrhosis, sponsored by University Hospital, Bonn. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-05.
Sponsored by University Hospital, Bonn · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Liver Cirrhosis with a site in Germany — 24 open to participants now, 27 under way, 2 of them phase 3. Liver Cirrhosis · Germany.
Among the 82 studies in Liver Cirrhosis with a site in Germany, this one is the 15th largest by planned enrollment of the 37 observational ones that give a count, is one of 7 that started in 2018, is one of 37 observational ones, reaches primary completion later than 6 of the 26 other live ones, and was the 35th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →24 of the 82 studies in Liver Cirrhosis with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Muenster · Sites in Germany
Ages 18+
University Medical Center Groningen · Sites in Germany, Austria, Belgium and 9 more countries
Ages 18+
Hannover Medical School · Sites in Germany
Ages 18–99 · Healthy volunteers
University Hospital Freiburg · Sites in Germany
Ages 18–80
Boehringer Ingelheim · Sites in Germany, United States, Argentina and 34 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 20 · Phase 3 8 · Phase 4 3
First in 2000; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 110 across the 43 interventional studies, 200 across the 37 observational. Of the 51 that completed or were terminated, 18 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 82 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bonn is the lead sponsor of 154 studies on the registry; 28 are open to participants now.
University Hospital, Bonn has 3 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Liver Cirrhosis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 82 studies in Liver Cirrhosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The principal aim of this study is to analyse L3-SMI (skeletal muscle index) in a cohort of patients with decompensated liver cirrhosis and TIPS (transjugular intrahepatic portosystemic shunt), and compare the prognostic power with TPMT (transverse psoas muscle thickness). Furthermore, the role of myosteatosis, determined in CT by L3-SMI, MRI and ultrasound will be studied.
The principal aim of this study is to analyse L3-SMI (skeletal muscle index) in a cohort of patients with decompensated liver cirrhosis and TIPS (transjugular intrahepatic portosystemic shunt), and compare the prognostic power with TPMT (transverse psoas muscle thickness). Furthermore, the role of myosteatosis, determined in CT by L3-SMI, MRI and ultrasound will be studied.
Patients with liver cirrhosis of any etiology and CT scan available
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
computed tomography, magnetic resosnance imaging, ultrasound
Survival time
time of survival
Time frame: up to 60 months
Time to clinical acute decompensations
time to occurrence of acute decompensations of liver cirrhosis (readmissions, hepatic encephalopathy, bleeding, ascites, hepatorenal syndrome, infections)
Time frame: up to 60 months
Time to clinical acute-on-chronic liver failure
acute-on-chronic liver failure according to EASL-CLIF-C definition (grade 1 (best) to 3 (worst)
Time frame: up to 60 months
Development of sarcopenia
Assessment of sarcopenia according to EASL-guideline
Time frame: up to 60 months
Started Jan 2018 (actual). Primary completion is estimated for Jul 2025, 90 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.